Black Diamond Therapeutics

OverviewSuggest Edit

Black Diamond Therapeutics is a biotechnology company. It is focused on the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.

TypePublic
Founded2017
HQCambridge, MA, US
Websiteblackdiamondtherapeutics.com

Latest Updates

Employees (est.) (Jan 2020)31(+4%)
Job Openings6
Revenue (FY, 2020)$0
Share Price (Sept 2021)$9.5(-4%)
Cybersecurity ratingAMore

Key People/Management at Black Diamond Therapeutics

David M. Epstein

David M. Epstein

Co-Founder, President & Chief Executive Officer and Director
Ali Behbahani

Ali Behbahani

Director
Brad Bolzon

Brad Bolzon

Director
Brent Hatzis-Schoch

Brent Hatzis-Schoch

Chief Operating Officer, General Counsel
Garry E. Menzel

Garry E. Menzel

Director
Alexander Mayweg

Alexander Mayweg

Director
Show more

Black Diamond Therapeutics Office Locations

Black Diamond Therapeutics has offices in Cambridge, New York, Stony Brook and Toronto
Cambridge, MA, US (HQ)
1 Main St
New York, NY, US
180 Varick St 6th floor
Stony Brook, NY, US
25 Health Sciences Drive
Toronto, CA
MaRS Centre for Impact Investing, West Tower, 661 University Ave Suite 1300
Show all (4)

Black Diamond Therapeutics Financials and Metrics

Black Diamond Therapeutics Revenue

USD

Net income (Q1, 2021)

(30.3m)

EBIT (Q1, 2021)

(30.7m)

Market capitalization (17-Sept-2021)

343.5m

Closing stock price (17-Sept-2021)

9.5

Cash (31-Mar-2021)

14.1m

EV

343.7m
Black Diamond Therapeutics's current market capitalization is $343.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

6.7m2.0m7.6m21.4m

R&D expense

3.5m7.0m21.8m48.2m

Operating expense total

4.1m8.9m29.3m69.6m
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

General and administrative expense

5.5m4.9m7.9m

R&D expense

7.4m10.2m22.8m

Operating expense total

12.9m15.0m30.7m

EBIT

(12.9m)(15.0m)(30.7m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.9m51.7m154.7m34.6m

Prepaid Expenses

36.0k24.0k1.0m4.5m

Current Assets

7.9m51.7m155.7m319.6m

PP&E

102.0k134.0k164.0k385.0k
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

78.7m357.2m64.0m14.1m

Prepaid Expenses

294.0k4.9m3.8m7.3m

Current Assets

79.0m362.1m208.2m297.3m

PP&E

116.0k154.0k166.0k791.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(4.6m)(8.9m)(35.3m)(67.3m)

Depreciation and Amortization

24.0k44.0k47.0k52.0k

Accounts Payable

(59.0k)264.0k1.5m1.1m

Cash From Operating Activities

(2.4m)(8.5m)(24.7m)(52.1m)
Quarterly
USDQ3, 2018Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(5.9m)(25.4m)(12.1m)(26.7m)(30.3m)

Depreciation and Amortization

32.0k38.0k10.0k23.0k19.0k

Accounts Payable

337.0k496.0k2.4m(1.4m)2.0m

Cash From Operating Activities

(6.1m)(17.2m)(11.3m)(24.9m)(24.5m)
USDFY, 2017

Financial Leverage

-1.2 x
Show all financial metrics

Black Diamond Therapeutics Operating Metrics

Jan, 2020

Patent Applications

7
Show all operating metrics

Black Diamond Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Black Diamond Therapeutics (Canada) Inc
Black Diamond Therapeutics Security Corporation

Black Diamond Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Black Diamond Therapeutics Online and Social Media Presence

Embed Graph

Black Diamond Therapeutics News and Updates

Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today reported financial results for the second quarter ended Jun…

Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. t…

Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions

Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today reported financial results for the first quarter ended March…

Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented
Show more

Black Diamond Therapeutics Frequently Asked Questions

  • When was Black Diamond Therapeutics founded?

    Black Diamond Therapeutics was founded in 2017.

  • Who are Black Diamond Therapeutics key executives?

    Black Diamond Therapeutics's key executives are David M. Epstein, Ali Behbahani and Brad Bolzon.

  • How many employees does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has 31 employees.

  • Who are Black Diamond Therapeutics competitors?

    Competitors of Black Diamond Therapeutics include Carna Biosciences, NMS Group and Revolution Medicines.

  • Where is Black Diamond Therapeutics headquarters?

    Black Diamond Therapeutics headquarters is located at 1 Main St, Cambridge.

  • Where are Black Diamond Therapeutics offices?

    Black Diamond Therapeutics has offices in Cambridge, New York, Stony Brook and Toronto.

  • How many offices does Black Diamond Therapeutics have?

    Black Diamond Therapeutics has 4 offices.